EORTC 2014: A Humanized Mouse Model for Preclinical Testing of Molecules Targeting Immune Checkpoints

Title
A Humanized Mouse Model for Preclinical Testing of Molecules Targeting Immune Checkpoints

Authors
Gilson S. Baia1, David Vasquez-Dunddel1, Daniel Ciznadija1, David Sidransky2, Amanda Katz1, Keren Paz11Champions Oncology, Inc, Baltimore, MD; 2The Johns Hopkins School of Medicine, Baltimore, MD

First Presented
EORTC 2014

Abstract
The blockade of immune checkpoints is a promising therapeutic avenue for cancer therapy, with durable objective responses observed in patients with a variety of solid tumors. Despite these successes, current animal models do not reliably identify targets with the greatest clinical potential due in part to differences between human and murine immune systems. Hence, robust preclinical tools to test these drugs directly against human cancers in the context of a human immune system are required. To circumvent this limitation, Champions Oncology has developed the ImmunoGraft, whereby two innovative technologies, the Champions TumorGraft (patient-derived xenograft) and humanized mice (immunodeficient mice reconstituted with a human immune system), are combined in a single platform.

Champions Oncology - Specializing in | Personalized Cancer Therapy | Translational Oncology Solutions | Oncology drug development | Oncology drug discovery | Translational oncology | Translation oncology research | Predictive oncology | Patient-derived xenograft model | Tumorgrafts | Alternative/new cancer treatment | Anticancer therapies | Personalized cancer treatment | Personalized cancer therapy | Personalized oncology